Genetic Test Evaluation

understanding how genetic tests impact patient management

Overa (ASPiRA Labs)

February 1, 2018

At present, the overall estimated 5-year survival rate for ovarian cancer is 46.5%. Early identification does impact prognosis; however, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, where survival rates are low. Biomarker analysis for risk stratification assessments for ovarian cancer, specifically adnexal masses, aims to increase early diagnosis and subsequent benefit from early intervention.